SOURCE: INC Research

INC Research

March 03, 2011 07:01 ET

New Chief Financial Officer Joins INC Research

David Gill Brings Extensive Life Sciences and Technology Experience to Global CRO

RALEIGH, NC--(Marketwire - March 3, 2011) - INC Research, LLC., a therapeutically focused contract research organization (CRO) with a trusted process for delivering reliable results, today announced its new chief financial officer (CFO), David Gill, who has built a career of building high-performing companies and managing rapid growth.

"David clearly understands the company's opportunities and challenges in delivering clinical trials outsourcing services on a global scale," said James Ogle, chief executive officer, INC Research. "We are excited to have David help lead the company through our next chapter as a top 10 CRO."

Gill was selected as a result of a national search of highly experienced executives in their field. For the past 20 years, he has held various executive roles with high-growth life sciences and information technology companies. During his tenure, revenue and shareholder value have significantly increased at each company. Most recently Gill served as the CFO of Transenterix, a surgical products company based in Morrisville, NC, where oversaw the completion of $55 million series B round of funding in 2009. He has taken three companies public and has executed several large equity financing transactions totaling more than $500 million. In addition, he has served on the board of directors of several life science companies over the past five years, including Calypso Medical Technologies, LeMaitre Vascular and IsoTis. He also served as an INC Research board member and chairman of the audit committee from 2007 to 2010.

Gill received a Master's of Business Administration with distinction from Emory University and a Bachelor's of Science degree, cum laude, in Accounting from Wake Forest University, and was formerly a Certified Public Accountant. He is a frequent presenter at investment conferences and is well known within the healthcare industry.

Gill is replacing Dan Hartnett who announced his retirement. In his tenure with INC Research, Hartnett played a pivotal leadership role, particularly in the past two years where he helped complete the company's largest and most significant acquisition to date, as well as completing a major recapitalization event, both of which helped position INC Research as a top 10 CRO and for continued growth as a global drug development outsourcing company.

INC Research is a privately held, therapeutically focused global contract research organization with deep expertise in managing global Phase I through Phase IV clinical development programs. INC Research employs more than 2,000 people in 40 countries worldwide. The full-service CRO was recently ranked 10th on the list of Preferred CROs, an annual survey conducted by William Blair and was number 10 on the Scrip Clinical Research 25 list based on 2009 revenues.

About INC Research, LLC.
INC Research is a therapeutically focused contract research organization with a high performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in therapeutic areas of specialty, and in innovative pediatric and women's health trials. The company's Trusted Process® methodology and therapeutic foresight leads customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information please visit www.incresearch.com or follow us at @inc_research.

Contact Information